Home / Market News / $CLDX
benzinga Corporate Catalyst Impact 55/100 ● neutral

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

Oct 2, 2026, 12:37 PM UTC · Primary ticker $CLDX

This filing discloses that HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating and maintained a $64 price target for Celldex Therapeutics. This indicates continued analyst confidence in the company's prospects, which could provide some positive sentiment for investors.

HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a 'Buy' rating and a $64 price target for Celldex Therapeutics. This action signals that the analyst's investment thesis for CLDX remains unchanged and positive. For traders, this reiteration could provide a short-term boost in investor confidence, potentially leading to some upward price movement or stabilization. Long-term, it reinforces the analyst's belief in the company's fundamental value. The key opportunity for traders is to consider this analyst's continued endorsement as a potential signal of underlying strength, though it's important to note that analyst ratings are just one factor in investment decisions.

$CLDX positive Analyst reiterates Buy rating and price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.